T Cell Immunity Testing

Examining T Cell Immune Response for Critical Decisions

Innovations in Immunity

inSIGHT™ T Cell diagnostic delivers a deeper understanding of patients' response to viral antigens

Assess current immune response for viral target
Confirm if virus specific CD4 and CD8 T Cells are present
Evaluate treatment decisions

Eurofins Viracor inSIGHT Logo

Learn more about Eurofins Viracor inSIGHT™ for examining T cell response:

CMV T Cell Immunity Test EBV T Cell Immunity Test

EBV inSIGHT™ T Cell Immunity test is now available to order.

The test measures the strength of T cell responses to EBV specific antigens, lytic antigen BZLF1 and latent antigen EBNA3. It evaluates and reports polyfunctional and Interferon-gamma activity of CD4 and CD8 T cell responses independently.

In the transplant setting, post-transplant lymphoproliferative disorders (PTLD) can arise as a consequence of immunosuppression and the loss of T cells that typically control reactivation of EBV. Rapidly rising EBV viral loads can indicate patients at risk for PTLD, a critical cause of morbidity and mortality in, SOT and HSCT patients

It's your job to keep patients safe; our job is to help you do it.

The Advantages of inSIGHT™

With inSIGHT™, you're now armed with the data to help answer critical questions: Is the patient's body producing a T Cell response? Is that response strong enough to make treatment adjustments? Are they ready to discontinue antiviral medication?

For Clinical Staff

Reports CD4 and CD8 responses separately
Provides numerical values for various reportables
Ability for result consultation with scientific liaisons

For Lab Staff

Does not require additional staff or training
Live cell ambient shippers available
Simple blood draw, no extra processing to isolate PBMC

CASE STUDY: Review a bi-lateral lung transplant patient case study to see how they utilized inSIGHT testing to evaluate prophylaxis.

CMV Immunity Testing in a Lung Transplant Recipient

CMV inSIGHT T Cell Immunity Testing Case Study

Addressing CMV in Solid Organ Transplant Patients with CMV inSIGHT^TM T Cell Immunity

Justin Rosenheck, DO
Assistant Professor of Internal Medicine at Ohio State University

Dr Kapil Kumar Saharia, MD, MPH
Chief, Solid Organ Transplant Infectious Disease at University of Maryland School of Medicine

Dr. Abhay Dhand, MD, FIDSA
Director of Transplant Infectious Disease at Westchester Medical Center

These knowledgeable physicians share how they manage their solid organ transplant patients at risk for CMV by utilizing CMV inSIGHT™ T Cell immunity. These unique case studies will cover situations like neutropenia, low-level CMV, the importance of CD4 T Cells and more. Learn when they use CMV inSIGHT T Cell Immunity testing to evaluate CMV-specific cell mediated immunity, what they do with the information from the lab report, and the outcomes of their patients. Including a recording of the Live Q&A at the end of the original presentation.

In this webinar you will learn how the physicians utilize CMV inSIGHT in the following solid organ transplant cases:

Neutropenic patient
Low-level CMV DNAemia
Importance of CD4 T Cell Response
In instances of CMV Resistance
When belatacept is used for immunosuppression

VIEW RESOURCE

Tailoring CMV Prophylaxis Based on a CMV T Cell Immunity Panel Assay in Kidney Transplant Patients

Presented By:
Dr. Clifford Miles, MD, FAST
Associate Professor
Internal Medicine-Nephrology
University of Nebraska Medical Center
Medical Director, Kidney & Pancreas Transplantation, Nebraska Medicine

This interesting presentation will review The University of Nebraska's Kidney Transplant program's strategy of using CMV inSIGHT T Cell Immunity testing to serially monitor high risk kidney transplant patients to evaluate if prophylaxis could be discontinued early. Dr. Clifford Miles will review data originally presented at the Cutting Edge of Transplantation earlier this year. Dr. Miles is the Medical Director of Kidney and Pancreas Transplant at the University of Nebraska's Medical Center and Associate Professor, Nephrology Division at UNMC's college of medicine.

Including a special Q&A between authors of the study.

VIEW RESOURCE

The ability to monitor the presence or absence of virus specific, highly functional T cells will be an important tool, along with monitoring viral load, in managing patients post-transplant as their immune system recovers."
~ Eurofins Viracor

Flebbe Rehwaldt EBV T Cell Immunity Abstract Poster

ABSTRACT POSTER PRESENTATION

Detection of Epstein-Barr Virus Specific Functional T Cells By Flow Cytometry

The ability to evaluate EBV specific T cell responses post-transplant is currently an unmet need for managing patients at risk of developing post-transplant lymphoproliferative disorder (PTLD). Functional impairment or lack of a T cell response to EBV has been predicted to drive the development of PTLD. Research indicates...

View the full poster presentation

Flebbe-Rehwaldt, L. Detection of Epstein-Barr Virus Specific Functional T Cells by Flow Cytometry. In: The 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR; April 23-26; Salt Lake City, UT; Abstract Number 479.

Results Reporting

RESULTS FOR:

EBV inSIGHT™ T Cell Immunity

Polyfunctional Index for EBV Antigens: CD4 EBV Cell Lysate, CD8 BZLF1 (lytic), CD8 EBNA 3A/3C (latent)
IFN-gamma Response for: CD4 EBV Cell Lysate, CD8 BZLF1 (lytic), CD8 EBNA 3A/3C (latent)
Control
Cell Viability

33217 - EBV inSIGHT™ T Cell Immunity

EBV inSIGHT™ T Cell Immunity Sample Report

Results For:

CMV inSIGHT™ T Cell Immunity

CMV Antigen
CD4
CD8
Control
Cell Viability

30360 - CMV inSIGHT™ T Cell Immunity Panel

WHITE PAPER

Evaluating Cytomegalovirus Cell Mediated Immunity Diagnostic Assays

T Cell Immunity Testing - Flow Cytometry

How It Works

inSIGHT™ utilizes intracellular cytokine staining analyzed by flow cytometry to measure the strength of T cell responses to viral specific antigens or proteins. It evaluates and reports the activity of CD4 and CD8 T Cell responses separately.

Chat With An Expert